Author: Author

ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
April 13, 2022 Off

ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177

By Author

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, today announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. Lu / EndolucinBeta) for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a. Lu-EBTATE to treat a range of cancers.

GSK Buys Sierra Oncology for $1.9bn
April 13, 2022 Off

GSK Buys Sierra Oncology for $1.9bn

By Author

GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (£1.5 billion).

Bayer receives approval for precision oncology treatment Vitrakvi in China
April 13, 2022 Off

Bayer receives approval for precision oncology treatment Vitrakvi in China

By Author

The Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Bayer’s larotrectinib, under the brand name Vitrakvi, for the treatment of adult and pediatric patients with advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NTRK gene fusions should be identified by a sufficiently validated test.